PRESS RELEASE published on 02/27/2025 at 08:57, 1 month 23 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie ses résultats financiers estimés pour l'année 2024. L'entreprise prolonge son horizon de trésorerie jusqu'à avril 2025 grâce à une gestion rigoureuse et au Crédit d'Impôt Recherche Résultats Financiers Trésorerie GenSight Biologics Crédit D'Impôt Recherche AAC
PRESS RELEASE published on 02/27/2025 at 08:57, 1 month 23 days ago Inside Information / News release on accounts, results GenSight Biologics reports estimated full-year 2024 consolidated financial results. Cash runway extended to early April 2025. Resumption of Compassionate Access Program expected in April 2025 Financial Results 2024 GenSight Biologics Cash Runway Compassionate Access Program
BRIEF published on 02/12/2025 at 07:35, 2 months 10 days ago GenSight Biologics Reports Positive Five-Year Outcomes for LUMEVOQ® Gene Therapy Gene Therapy LUMEVOQ® Visual Acuity Safety Profile REFLECT Study
BRIEF published on 02/12/2025 at 07:35, 2 months 10 days ago GenSight Biologics annonce des résultats positifs sur cinq ans pour la thérapie génique LUMEVOQ® Thérapie Génique LUMEVOQ® Acuité Visuelle Profil De Sécurité Étude REFLECT
PRESS RELEASE published on 02/12/2025 at 07:30, 2 months 10 days ago Informations privilégiées / Autres communiqués GenSight Biologics annonce les résultats à 5 ans de la thérapie génique LUMEVOQ® pour la NOHL, confirmant l'efficacité durable et le profil de sécurité favorable Sécurité Efficacité Thérapie Génique GenSight Biologics LUMEVOQ
PRESS RELEASE published on 02/12/2025 at 07:30, 2 months 10 days ago Inside Information / Other news releases GenSight Biologics reports 5-year efficacy and safety results for LUMEVOQ® gene therapy in REFLECT study with sustained visual improvement and favorable safety profile Gene Therapy GenSight Biologics LUMEVOQ Visual Acuity REFLECT Study
BRIEF published on 01/23/2025 at 18:50, 2 months 30 days ago GenSight Biologics : Bilan Financier et Perspectives GenSight Biologics LUMEVOQ® Augmentations De Capital Accès Compassionnel Trésorerie 2024
BRIEF published on 01/23/2025 at 18:50, 2 months 30 days ago GenSight Biologics: Financial Report and Outlook GenSight Biologics Capital Increases LUMEVOQ® Compassionate Access Treasury 2024
PRESS RELEASE published on 01/23/2025 at 18:45, 2 months 30 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie sa situation financière 2024 et donne des mises à jour sur ses activités, y compris le financement et la progression réglementaire de LUMEVOQ. La trésorerie s'élève à 2,5M€ à fin 2024 Financement Trésorerie Situation Financière GenSight Biologics LUMEVOQ
PRESS RELEASE published on 01/23/2025 at 18:45, 2 months 30 days ago Inside Information / News release on accounts, results GenSight Biologics reports end-of-year cash position and provides business update, including successful capital increases and ongoing review of LUMEVOQ dossier Business Update Cash Position GenSight Biologics Capital Increases LUMEVOQ Dossier
Published on 04/22/2025 at 19:55, 3 hours 15 minutes ago CEO Spotlight: How Mangoceuticals Inc. is Reinventing The Personal Health Landscape
Published on 04/22/2025 at 19:45, 3 hours 25 minutes ago NewsOut Launches Weekly Video Press Release Coverage on Tesla, Amazon, Apple, NVIDIA, and Microsoft
Published on 04/22/2025 at 15:45, 7 hours 25 minutes ago Alaska Energy Metals Files Updated NI 43-101 Technical Report for The Eureka Deposit, Nikolai Nickel Project, Alaska, USA
Published on 04/22/2025 at 15:15, 7 hours 55 minutes ago Silver Bull Announces Voting Results of Annual Meeting of Shareholders
Published on 04/22/2025 at 15:15, 7 hours 55 minutes ago D. Boral Capital Acted as Exclusive Placement Agent to Safe & Green Holdings Corp. (Nasdaq: SGBX) in Connection with Its Approximately $8.0 Million Private Placement
Published on 04/22/2025 at 22:26, 43 minutes ago EQS-Adhoc: Allane SE: Deviation of earnings forecast for financial year 2024, postponement of publication of annual and consolidated financial statements and AGM, no dividend distribution for 2024
Published on 04/22/2025 at 22:05, 1 hour 5 minutes ago Abivax annonce les modalités de son Assemblée Générale Annuelle alors que la Société se rapproche d’étapes clés créatrices de valeur en 2025
Published on 04/22/2025 at 22:05, 1 hour 5 minutes ago Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones
Published on 04/22/2025 at 22:00, 1 hour 10 minutes ago Abivax annonce la nomination du Dr Dominik Höchli au sein de son Conseil d’administration
Published on 04/22/2025 at 22:00, 1 hour 10 minutes ago Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors
Published on 04/22/2025 at 18:13, 4 hours 56 minutes ago ELECTRICITE DE STRASBOURG - Droits de vote au jour de l'avis de réunion de l'AGO du 14 mai 2025
Published on 04/22/2025 at 18:12, 4 hours 57 minutes ago ELECTRICITE DE STRASBOURG - Avis de mise à disposition des rapports 2024, des rapports des CAC et des états financiers
Published on 04/22/2025 at 17:57, 5 hours 13 minutes ago NRJ Group - AGM 15 mai 2025 - Mise à disposition des documents préparatoires
Published on 04/22/2025 at 17:57, 5 hours 13 minutes ago Annual Shareholders' Meeting 2025 - Conditions of availability of the preparatory documents
